Hot Natural Products & Bioactive Compounds
BioCrick offers high-purity natural products and bioactive compounds for scientific research. Our natural product collection includes compounds derived from plants, microorganisms and other biological sources and is widely used in pharmacological, biochemical and drug discovery research.
Natural products remain an important source of bioactive molecules and drug leads. BioCrick provides researchers with high-quality natural product compounds together with catalog numbers, product information and biological activity data.
Hot Products from BioCrick
Showing 793 - 800 of 9359 hot products
| Catalog No. | Product Name |
|---|---|
| BCC4179 | GSK 2830371 |
|
Potent and selective allosteric inhibitor of Wip1 phosphatase (IC50 = 6 nM). Exhibits selectivity for Wip1 over 21 other phosphatases. Increases phosphorylation of Wip1 substrates, including p53, Chk2, H2AX and ATM. Attenuates tumor cell growth in a variety of lymphoid cell lines. Also inhibits lymphoma xenograft growth in vivo. Potentiates growth inhibitory effects of MDM2 inhibition in cancer cell lines in a p53-dependent manner. Orally bioavailable.
|
|
| BCC4199 | TRPC6 inhibitor |
|
Potent TRPC6 inhibitor (IC50 values are 9.5, 226 and 282 nM for TRPC6, TRPC7 and TRPC3-mediated Ca2+ influx). Exhibits no significant activity at TRPC4 and TRPC5 channels. Suppresses TRPC6-dependent acute hypoxic pulmonary vasoconstriction (HPV) in the isolated perfused mouse lung. Orally bioavailable.
|
|
| BCC4200 | CC0651 |
|
Allosteric inhibitor of human Cdc34. Inhibits hCdc34-mediated ubiquitination of p27<sup>Kip1</sup> (IC<sub>50</sub> = 1.72 <span class='symbol'>μ</span>M). Exhibits selectivity for hCdc34 over Uba1, Ube2G1, UbcH7, UbcH5, Ube2N (Ubc13), Ube2R2, SMURF2, SspH1 and Rnf168.
|
|
| BCC4207 | Cisapride |
|
5-HT4 receptor agonist and gastrokinetic agent. Stimulates intestinal acetylcholine release, possibly via 5-HT4 receptor-dependent and -independent mechanisms, leading to increased intestinal motility.
|
|
| BCC4219 | Aniracetam |
|
Nootropic, with modulatory actions through allosteric potentiation of AMPA specific receptors, reduction of glutamate receptor desensitization and potentiation of metabotropic glutamate receptor activity. Anxiolytic following systemic administration.
|
|
| BCC4232 | Vancomycin hydrochloride |
|
Antibiotic with activity against Gram-positive bacteria.
|
|
| BCC4244 | NVP 231 |
|
Potent, selective and reversible ceramide kinase (CerK) inhibitor (IC<sub>50</sub> = 12 nM <em>in vitro</em>). Displays selectivity for CerK over sphingosine kinases (IC<sub>50</sub> ≥100 <span class='symbol'>μ</span>M) and other lipid kinases.
|
|
| BCC4246 | LH846 |
|
Selective inhibitor of casein kinase (CK) 1<span class='symbol'>δ</span> (IC<sub>50</sub> values are 290 nM, 1.3 <span class='symbol'>μ</span>M and 2.5 <span class='symbol'>μ</span>M for CK1<span class='symbol'>δ</span>, <span class='symbol'>ε</span> and <span class='symbol'>α</span>); displays no inhibitory activity at CK2. Inhibits CK1<span class='symbol'>δ</span>-dependent phosphorylation and degradation of PER1 protein. Shown to lengthen the circadian period in U2OS cells, with minimal effect on amplitude.
|
|